Earnings summaries and quarterly performance for Relay Therapeutics.
Executive leadership at Relay Therapeutics.
Board of directors at Relay Therapeutics.
Research analysts covering Relay Therapeutics.
Recent press releases and 8-K filings for RLAY.
Relay Therapeutics announces positive zovegalisib efficacy data from ReDiscover study subset analysis
RLAY
New Projects/Investments
- Relay Therapeutics presented a subset analysis of interim clinical data for zovegalisib (RLY-2608), an investigational PI3Kα inhibitor, at the 2025 San Antonio Breast Cancer Symposium.
- The data showed a 10.3-month median Progression-Free Survival (PFS) for all patients and 11.4-month median PFS for second-line (2L) patients.
- Efficacy was consistent across subgroups, including patients with prior SERD exposure (median PFS 11.4 months, ORR 44%) and those with detectable ESR1 mutations (median PFS 8.8 months, ORR 60%).
- The company is continuing enrollment in the Phase 3 ReDiscover-2 trial for breast cancer and the Phase 1/2 ReInspire clinical trial for vascular malformations.
Dec 12, 2025, 12:00 PM
Relay Therapeutics Provides Update on RLY-2608 Phase 3 Progress and Financial Position
RLAY
New Projects/Investments
Guidance Update
- Relay Therapeutics is in execution mode for its Phase 3 asset, RLY-2608, a PI3K alpha mutant selective inhibitor, which has shown a 39% ORR and 10.3-month PFS (11 months in pure second line).
- The company is confident that RLY-2608 will be successful in the second-line setting, aiming for a 2-3 month PFS delta over Capivasertib.
- Relay Therapeutics has close to $600 million on its balance sheet, providing a cash runway into 2029, which supports ongoing trials including Rediscovery II (Phase 3), triplet data, and vascular malformations programs.
- The company is also exploring triplet regimens for earlier breast cancer treatment and has commenced dosing patients with PI3K alpha-driven vascular malformations.
Nov 19, 2025, 11:30 AM
Relay Therapeutics Provides Update on RLY-2608 Phase 3 Progress and Pipeline
RLAY
New Projects/Investments
- Relay Therapeutics is in execution mode with its Phase 3 asset RLY-2608, a PI3K alpha mutant selective inhibitor, for breast cancer, targeting a 10-month PFS in the second-line setting against a competitive bar of 5.5 to 7 months.
- The company has commenced dosing patients with PI3K alpha-driven vascular malformations with RLY-2608, representing a significant opportunity with 170,000 patients across all types of vascular malformations.
- Relay Therapeutics maintains a strong financial position with close to $600 million on its balance sheet, providing a cash runway into 2029 to support ongoing clinical trials and pipeline development.
- RLY-2608 is being compared against Capivasertib in the Rediscovery II study, with an internal target of a two to three-month delta in PFS, and is differentiated by its 400-mg BID Fed dose and a potentially cleaner safety profile, particularly regarding hyperglycemia, compared to other PI3K alpha inhibitors.
Nov 19, 2025, 11:30 AM
Relay Therapeutics Provides Update on RLY-2608 Phase III Progress and Pipeline
RLAY
New Projects/Investments
Guidance Update
- Relay Therapeutics is in Phase III with its PI3K alpha mutant selective inhibitor, RLY-2608, for breast cancer, targeting a 10-month PFS (11 months in second-line only) against Capivasertib, which has a 5.5-7 month PFS. The ReDiscover-2 study is powered for a 2-3 month delta over Capivasertib.
- RLY-2608 will use a 400-mg BID Fed dose, which maintains similar PK coverage to previous doses. The company anticipates lower hyperglycemia rates compared to other PI3K alphas, and at-home glucose monitoring is not required for RLY-2608 in the ReDiscover-2 study.
- The company has commenced dosing patients for PI3K alpha-driven vascular malformations, utilizing a dose randomization approach across three doses, aiming for improved efficacy and tolerability compared to existing treatments.
- Relay Therapeutics holds close to $600 million on its balance sheet, providing a cash runway into 2029.
Nov 19, 2025, 11:30 AM
Relay Therapeutics Discusses RLY-2608 Clinical Progress and Market Opportunities
RLAY
New Projects/Investments
Product Launch
Guidance Update
- Relay Therapeutics is advancing RLY-2608, a PI3Kα mutant selective inhibitor, with a pivotal trial in post-CDK4/6 metastatic breast cancer started this summer, and ongoing trials for frontline metastatic breast cancer and vascular malformations.
- RLY-2608 demonstrates a superior clinical profile in breast cancer compared to capivasertib, showing double-digit progression-free survival (PFS) versus 5.5 months for capivasertib, and a 39% confirmed objective response rate compared to 20% for a competitor molecule.
- The company sees a significant commercial opportunity for RLY-2608 in vascular malformations, targeting an estimated 170,000 PI3Kα mutant patients in the U.S., with potential for a multi-billion dollar market.
- Relay Therapeutics has a cash runway extending into 2029.
Nov 10, 2025, 4:00 PM
Relay Therapeutics Reports Q3 2025 Financial Results and Board Appointments
RLAY
Earnings
Board Change
- Relay Therapeutics reported a net loss of $74.1 million and a net loss per share of $0.43 for the third quarter of 2025.
- As of September 30, 2025, the company held approximately $596.4 million in cash, cash equivalents, and investments, which is expected to fund operating expenses and capital expenditure requirements into 2029.
- Lonnel Coats and Habib Dable, both former biotech CEOs with launch and commercialization expertise, were appointed to Relay Therapeutics' Board of Directors, effective November 4, 2025.
- The company is continuing the Phase 3 ReDiscover-2 trial and Phase 1/2 ReDiscover trial for RLY-2608 in breast cancer, and the Phase 1/2 ReInspire clinical trial in vascular malformations.
Nov 6, 2025, 9:12 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more